<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) - Goldkuhle, M - 2018 | Cochrane Library</title> <meta content="Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) - Goldkuhle, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012556.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) - Goldkuhle, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012556.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012556.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)" name="citation_title"/> <meta content="Marius Goldkuhle" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Maria Dimaki" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Gerald Gartlehner" name="citation_author"/> <meta content="Danube University Krems" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Jan‐Peter Glossmann" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Andreas Engert" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Bastian von Tresckow" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012556.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012556.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012556.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012556.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [*therapeutic use]; Antineoplastic Agents [*therapeutic use]; Hodgkin Disease [*drug therapy, pathology]; Nivolumab; Software" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012556.pub2&amp;doi=10.1002/14651858.CD012556.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012556\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012556\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","ja","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012556.pub2",title:"Nivolumab for adults with Hodgkin\u0027s lymphoma (a rapid review using the software RobotReviewer)",firstPublishedDate:"Jul 12, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012556.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012556.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012556.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012556.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012556.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012556.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012556.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012556.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012556.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012556.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5311 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012556.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/appendices#CD012556-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0002">Marius Goldkuhle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0003">Maria Dimaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0004">Gerald Gartlehner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0005">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0006">Philipp Dahm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0007">Jan‐Peter Glossmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0008">Andreas Engert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0009">Bastian von Tresckow</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information#CD012556-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information/en#CD012556-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012556.pub2">https://doi.org/10.1002/14651858.CD012556.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012556-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012556-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012556-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012556-abs-0001" lang="en"> <section id="CD012556-sec-0001"> <h3 class="title" id="CD012556-sec-0001">Background</h3> <p>Hodgkin's lymphoma (HL) is a cancer of the lymphatic system, and involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage. With cure rates of up to 90%, HL is one of the most curable cancers worldwide. Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high‐dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of participants treated with high‐dose chemotherapy and ASCT are free from treatment failure at three years, with an overall survival (OS) of about 80% at three years. </p> <p>Checkpoint inhibitors that target the interaction of the programmed death (PD)‐1 immune checkpoint receptor, and its ligands PD‐L1 and PD‐L2, have shown remarkable activity in a wide range of malignancies. Nivolumab is an anti‐(PD)‐1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non‐small cell lung cancer, renal cell carcinoma and, since 2016, for classical Hodgkin's lymphoma (cHL) after treatment with ASCT and brentuximab vedotin. </p> </section> <section id="CD012556-sec-0002"> <h3 class="title" id="CD012556-sec-0002">Objectives</h3> <p>To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease). </p> </section> <section id="CD012556-sec-0003"> <h3 class="title" id="CD012556-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, International Pharmaceutical Abstracts, conference proceedings and six study registries from January 2000 to May 2018 for prospectively planned trials evaluating nivolumab. </p> </section> <section id="CD012556-sec-0004"> <h3 class="title" id="CD012556-sec-0004">Selection criteria</h3> <p>We included prospectively planned trials evaluating nivolumab in adults with HL. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors. </p> </section> <section id="CD012556-sec-0005"> <h3 class="title" id="CD012556-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed potential risk of bias. We used the software RobotReviewer to extract data and compared results with our findings. As we did not identify any randomised controlled trials (RCTs) or non‐RCTs, we did not meta‐analyse data. </p> </section> <section id="CD012556-sec-0006"> <h3 class="title" id="CD012556-sec-0006">Main results</h3> <p>Our search found 782 potentially relevant references. From these, we included three trials without a control group, with 283 participants. In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised. Risk of bias of the three included studies was moderate to high. All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT. As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias. The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way. </p> <p>Two studies with 260 participants evaluated OS. After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow‐up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow‐up times (downgrading by 1 point)). In one study, one out of three cohorts reported quality of life. It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow‐up questionnaire (very low certainty evidence). Three trials (283 participants) evaluated progression‐free survival (PFS) (very low certainty evidence). Six‐month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months. All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence). </p> <p>One trial (243 participants) reported drug‐related grade 3 or 4 adverse events (AEs) only after a median follow‐up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow‐up (very low certainty evidence). Only one trial (243 participants) reported drug‐related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence). </p> <p>None of the studies reported treatment‐related mortality.</p> </section> <section id="CD012556-sec-0007"> <h3 class="title" id="CD012556-sec-0007">Authors' conclusions</h3> <p>To date, data on OS, quality of life, PFS, response rate, or short‐ and long‐term AEs are available from small uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median OS was not reached after follow‐up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint). Only one cohort out of three only reported quality of life, with limited follow‐up data so that meaningful conclusions were not possible. Serious adverse events occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that proper RCTs should confirm these findings. </p> <p>As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012556-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012556-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012556-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012556-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012556-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012556-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012556-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012556-abs-0003" lang="en"> <h3>Nivolumab for adults with Hodgkin's lymphoma</h3> <p><b>Background</b> </p> <p>Hodgkin's lymphoma (HL) is a cancer of the lymphatic system. As part of the immune system, the lymphatic system comprises a network of lymphatic vessels, which transport lymph throughout the body. Lymph is a fluid which contains white blood cells, that tackle infection. HL occurs in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer and up to 90% of people will be cured; however, approximately 10% of people with HL will relapse (the cancer will return). Treatment options are chemotherapy, radiotherapy, or both, or newly developed agents, called checkpoint inhibitors that target the cancer cell directly. Nivolumab is one checkpoint inhibitor and currently approved by the US Food and Drug Administration for the treatment of various cancers and relapsed HL after treatment with stem cell transplantation and brentuximab vedotin, which is a medicine used to treat cancer. In stem cell transplantation patients receive blood building cells, so called stem cells, which replace their own when they have been destroyed along the disease or previous therapy regimens. </p> <p><b>Review question</b> </p> <p>This systematic review evaluated the benefits and harms of nivolumab for adults with Hodgkin's lymphoma. </p> <p><b>Study characteristics</b> </p> <p>We searched important medical databases for clinical trials assessing the benefits and harms of nivolumab in adults with HL. Two review authors independently screened, summarised and analysed the results. In addition, we tested the computer software RobotReviewer to extract data. Our search led to the inclusion of three studies involving 283 participants and 14 ongoing trials. </p> <p>The evidence provided is current to May 2018.</p> <p><b>Key results</b> </p> <p>Two studies with 260 participants evaluated survival. After six months, all participants were alive in one trial (17 participants). One trial reported quality of life for a subgroup of participants using a questionnaire but not all follow‐up data were available. Although it seemed that the participants answering the questionnaire might have had a benefit, it was unclear whether this applied to all the participants. The studies also reported tumour control and tumour response, but with different results, depending on the treatment and how many previous treatments participants had received before nivolumab was given. </p> <p>As nivolumab is given until the disease progresses (gets worse) or until unacceptable side effects occur, people receive the drug for a long time. Therefore, reporting of side effects is related to the time the person received the medicine, with potentially more side effects with longer usage. The most commonly reported side effects were fatigue (tiredness), diarrhoea (loose stools), infusion reactions (during or shortly after giving the medicine by a vein) and rash. Only one study reported medicine‐related serious side effects. They occurred rarely (infusion reactions and lung disease). Deaths related to the medicine were not reported. </p> <p><b>Reliability of the evidence</b> </p> <p>Due to the study design and varied type of participants with different numbers of previous treatments and various treatment options, the reliability of the evidence was low to very low. </p> <p><b>Conclusion</b> </p> <p>This systematic review evaluated the benefits and harms of nivolumab in adults with HL. </p> <p>Data on survival, quality of life, tumour response and side effects were available from small trials only. The three trials included only people different previous treatment options, very often also with a previous stem cell transplantation. In one trial, all participants were alive after six months. Quality of life data were not reported for all the included participants; moreover, data after a long period of treatment were not available for all evaluated participants, therefore meaningful conclusions were not possible. Serious side effects occurred rarely. Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for those who had received several treatments before. As there are currently 14 ongoing trials evaluating nivolumab, of which two are well designed, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012556-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-sec-0094">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-sec-0170">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012556-sec-0094"></div> <h3 class="title" id="CD012556-sec-0095">Implications for practice</h3> <section id="CD012556-sec-0095"> <p>To date, data on overall survival, quality of life, progression‐free survival, response rate, or short‐ and long‐term adverse events are available from small non‐randomised, uncontrolled trials only. The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT. For these participants, median overall survival was not reached after follow‐up times of up to 16 to 23 months, depending on pretreatment, meaning that more than 50% of these heavily pretreated participants with a limited life expectancy were alive at 16 to 23 months. Complete response rates ranged between 12% and 29%. Quality of life data were reported for one cohort out of three only, with limited follow‐up data so that meaningful conclusions are not possible. Serious adverse events occurred rarely. </p> <p>Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory Hodgkin's lymphoma except for heavily pretreated people, which had previously undergone regimens of BV or ASCT. When interpreting these results, it is important to consider that well‐designed randomised controlled trials should confirm these findings. </p> </section> <h3 class="title" id="CD012556-sec-0096">Implications for research</h3> <section id="CD012556-sec-0096"> <p>Randomised controlled trials or at least non‐randomised trials with a control group are needed to confirm findings of this review. As there are 14 ongoing trials evaluating nivolumab, of which two are randomised, it is possible that an update of this review will be published in the near future. It might well be that this update will show different results than those published in this systematic review. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012556-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012556-sec-0022"></div> <div class="table" id="CD012556-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Nivolumab compared to no other intervention for adults with Hodgkin's lymphomas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Nivolumab for adults with Hodgkin's lymphoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with Hodgkin's lymphoma </p> <p><b>Settings: i</b>npatient or outpatient cancer care </p> <p><b>Intervention:</b> nivolumab </p> <p><b>Comparison:</b> none </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impacts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS</b><br/> follow‐up: range 6‐27 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> reported that median OS has not been reached after a median follow‐up of 18 months. <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> reported 100% OS after 6 months. </p> <p>A retrospective analysis of participants with third relapse of cHL not treated with nivolumab shows a 6‐month OS of 90% and a 12 month OS of 73%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>260<br/> (2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b><br/> follow‐up: mean 7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Both the EQ‐5D visual analogue scale (and the EORTC QLQ‐C30 indicated improved QoL for those participants who filled out the forms. (EQ‐5D: from 62 (standard deviation (SD) 30) at baseline (72 (90%) participants) to 80 (SD 18) at week 33 (44 (55%) participants); EORTC QLQ‐C30 suggested improvement from baseline across functional, symptom and global health scores) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80<br/> (1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PFS</b><br/> follow‐up: range 6 months to 23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 trials reported 6‐month PFS of 60‐86%. In the other trial, median PFS was 12‐18 months. A retrospective analysis of third relapsed people with cHL not treated with nivolumab demonstrated a 6‐month PFS of 76% and a 12‐month PFS of 51%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response rate</b><br/> follow‐up: range 6‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Complete response rate was 12‐29% depending on inclusion criteria and participants' previous treatments </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 3 or 4 AEs</b><br/> follow‐up: range 8‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 trial reported drug‐related AEs only (fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%)). The other 2 trials reported 23% to 52% AEs. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SAEs</b><br/> follow‐up: range 16‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2% of participants had infusion reactions and 1% pneumonitis (drug‐related SAEs).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>243<br/> (1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE:</b> adverse event; <b>cHL:</b> classical Hodgkin's lymphoma; <b>CI:</b> confidence interval; <b>EORTC:</b> European Organisation for Research and Treatment of Cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>QoL:</b> quality of life; <b>SAE:</b> serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Since all included studies where uncontrolled studies, the certainty of the evidence for all outcomes started at "low" (2 points) </p> <p><sup>b</sup>Different study populations with different previous therapeutic regimen and various follow‐up times led to inconsistency (downgraded 1 point). </p> <p><sup>c</sup>Only a subset of participants was evaluated (cohort B, 80 participants, but only 44 filled out follow‐up data) (downgraded by 1 point). </p> <p><sup>d</sup>Small number of events leads to imprecision (downgraded 1 point). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012556-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-sec-0130">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012556-sec-0023"></div> <section id="CD012556-sec-0024"> <h3 class="title" id="CD012556-sec-0024">Description of the condition</h3> <p>Hodgkin's lymphoma (HL) is a cancer of the lymphatic system that involves the lymph nodes, spleen and other organs such as the liver, lung, bone or bone marrow, depending on the tumour stage (<a href="./references#CD012556-bbs2-0048" title="ListerTA , CrowtherD , SutcliffeSB , GlatsteinE , CanellosGP , YoungRC , et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology1989;7(11):1630‐6. ">Lister 1989</a>). The incidence of HL typically shows a bimodal age distribution with a first peak around the age of 30 years and a second peak after the age of 60 years. HL accounts for 10% to 15% of all lymphoma in industrialised countries, with an incidence of 2 to 3 per 100,000 inhabitants per year. It can therefore be regarded as a relatively rare disease, but is nevertheless one of the most common malignancies in young adults (<a href="./references#CD012556-bbs2-0067" title="ThomasRK , ReD , ZanderT , WolfJ , DiehlV . Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology2002;13 Suppl 4:147‐52. [PUBMED: 12401681] ">Thomas 2002</a>). </p> <p>The disease usually develops in lymph nodes in the upper part of the body, mostly the latero‐cervical lymph nodes, and results in painless swelling of the lymphatic tissue involved. Normally HL appears within these parts of the body, with peripheral extranodal involvement being rare. As a sign of large tumour size or spreading, 25% of people present with so‐called B‐symptoms, such as fever, drenching night sweats and a loss of more than 10% bodyweight (<a href="./references#CD012556-bbs2-0033" title="ConnorsJM . Clinical manifestations and natural history of Hodgkin's lymphoma. Cancer Journal2009;15(2):124‐8. ">Connors 2009</a>; <a href="./references#CD012556-bbs2-0054" title="PileriSA , AscaniS , LeonciniL , SabattiniE , ZinzaniPL , PiccalugaPP , et al. Hodgkin's lymphoma: the pathologist's viewpoint. Journal of Clinical Pathology2002;55(3):162‐76. [PUBMED: 11896065] ">Pileri 2002</a>). </p> <p>The World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues distinguishes between two types of HL: classic HL (cHL), which represents about 95% of all HL, and lymphocyte‐predominant HL, which represents about 5% of all HL (<a href="./references#CD012556-bbs2-0050" title="MathasS , HartmannS , KüppersR . Hodgkin lymphoma: Pathology and biology. Seminars in Hematology2016;53(3):139‐47. [PUBMED: 27496304] ">Mathas 2016</a>). The types differ in morphology, phenotype and molecular features, and therefore in clinical behaviour and presentation (<a href="./references#CD012556-bbs2-0056" title="ReD , ThomasRK , BehringerK , DiehlV . From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood2005;105(12):4553‐60. [PUBMED: 15728122] ">Re 2005</a>). </p> <p>The Ann Arbor Classification is used for staging and distinguishes between four different tumour stages (<a href="./references#CD012556-bbs2-0061" title="RosenbergSA , BoironM , DeVitaVTJr , JohnsonRE , LeeBJ , UltmannJE , et al. Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Research1971;31(11):1862‐3. [PUBMED: 5121695] ">Rosenberg 1971</a>). Stages I to III indicate the degree of lymph node and localised extranodal organ involvement or both, and stage IV includes disseminated organ involvement, which can be found in 20% of cases. Factors associated with a poor prognosis include a large mediastinal mass, three or more involved lymph node areas, a high erythrocyte sedimentation rate, extranodal lesions, B‐symptoms (weight loss greater than 10%, fever, drenching night sweats) and advanced age, but the factors considered clinically significant vary slightly between different study groups (German Hodgkin Study Group (GHSG), European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC)). HL is classified into early favourable, early unfavourable and advanced stage (<a href="./references#CD012556-bbs2-0037" title="EngertA , FranklinJ , EichHT , BrillantC , SehlenS , CartoniC , et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended‐field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology2007;25(23):3495‐502. ">Engert 2007</a>). In Europe, the early favourable‐stage group usually comprises Ann Arbor stages I and II without risk factors. The early unfavourable‐stage group includes people with Ann Arbor stages I or II and one or more risk factors. Most people with stages IIB, III or IV disease are included in the advanced‐stage risk group (<a href="./references#CD012556-bbs2-0036" title="EngertA , SchillerP , JostingA , HerrmannR , KochP , SieberM , et al. Involved‐field radiotherapy is equally effective and less toxic compared with extended‐field radiotherapy after four cycles of chemotherapy in patients with early‐stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(19):3601‐8. ">Engert 2003</a>). </p> <p>With cure rates of up to 90%, HL is one of the most curable cancers worldwide (<a href="./references#CD012556-bbs2-0038" title="EngertA , PlütschowA , EichHT , LohriA , DörkenB , BorchmannP , et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine2010;363(7):640‐52. [PUBMED: 20818855] ">Engert 2010</a>; <a href="./references#CD012556-bbs2-0039" title="EngertA , HaverkampH , KobeC , MarkovaJ , RennerC , HoA , et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet2012;379(9828):1791‐9. [PUBMED: 22480758] ">Engert 2012</a>; <a href="./references#CD012556-bbs2-0070" title="vonTresckowB , PlütschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30(9):907‐13. [PUBMED: 22271480] ">von Tresckow 2012</a>). A combination of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) is widely accepted as the gold‐standard chemotherapy regimen in people with HL (<a href="./references#CD012556-bbs2-0030" title="CanellosGP , AndersonJR , PropertKJ , NissenN , CooperMR , HendersonES , et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine1992;327(21):1478‐84. [PUBMED: 1383821] ">Canellos 1992</a>; <a href="./references#CD012556-bbs2-0038" title="EngertA , PlütschowA , EichHT , LohriA , DörkenB , BorchmannP , et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine2010;363(7):640‐52. [PUBMED: 20818855] ">Engert 2010</a>). People with limited‐stage disease usually receive a combination of chemotherapy and involved‐field radiation therapy (IF‐RT) (<a href="./references#CD012556-bbs2-0038" title="EngertA , PlütschowA , EichHT , LohriA , DörkenB , BorchmannP , et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine2010;363(7):640‐52. [PUBMED: 20818855] ">Engert 2010</a>; <a href="./references#CD012556-bbs2-0070" title="vonTresckowB , PlütschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30(9):907‐13. [PUBMED: 22271480] ">von Tresckow 2012</a>), whereas those with advanced‐stage disease usually receive an intensified regimen, such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) (<a href="./references#CD012556-bbs2-0026" title="BorchmannP , HaverkampH , DiehlV , CernyT , MarkovaJ , HoAD , et al. Eight cycles of escalated‐dose BEACOPP compared with four cycles of escalated‐dose BEACOPP followed by four cycles of baseline‐dose BEACOPP with or without radiotherapy in patients with advanced‐stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Journal of Clinical Oncology2011;29(32):4234‐42. [PUBMED: 21990399] ">Borchmann 2011</a>; <a href="./references#CD012556-bbs2-0039" title="EngertA , HaverkampH , KobeC , MarkovaJ , RennerC , HoA , et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet2012;379(9828):1791‐9. [PUBMED: 22480758] ">Engert 2012</a>; <a href="./references#CD012556-bbs2-0064" title="SkoetzN , TrelleS , RanceaM , HaverkampH , DiehlV , EngertA , et al. Effect of initial treatment strategy on survival of patients with advanced‐stage Hodgkin's lymphoma: a systematic review and network meta‐analysis. Lancet Oncology2013;14(10):943‐52. [PUBMED: 23948348] ">Skoetz 2013</a>) or ABVD. One large randomised trial showed that two cycles of ABVD followed by 20 Gy of IF‐RT is sufficient for the treatment of early‐favourable HL (<a href="./references#CD012556-bbs2-0038" title="EngertA , PlütschowA , EichHT , LohriA , DörkenB , BorchmannP , et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine2010;363(7):640‐52. [PUBMED: 20818855] ">Engert 2010</a>). Two cycles of escalated BEACOPP (BEACOPPesc) followed by two cycles of ABVD can improve progression‐free survival (PFS) in comparison to four cycles of ABVD in people with early‐unfavourable HL (<a href="./references#CD012556-bbs2-0070" title="vonTresckowB , PlütschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30(9):907‐13. [PUBMED: 22271480] ">von Tresckow 2012</a>). </p> <p>Approximately 10% of people with HL will be refractory to initial treatment or will relapse; this is more common in people with advanced stage or bulky disease. Standard of care for these people is high‐dose chemotherapy and autologous stem cell transplantation (ASCT), but only 55% of people treated with high‐dose chemotherapy and ASCT have been shown to be free from treatment failure at three years, with survival rated of about 80% at three years (<a href="./references#CD012556-bbs2-0055" title="RanceaM , MonsefI , vonTresckowB , EngertA , SkoetzN . High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009411.pub2; PUBMED: 23784872] ">Rancea 2013</a>). For people progressing after ASCT, brentuximab vedotin can improve PFS and is the preferred treatment (<a href="./references#CD012556-bbs2-0071" title="YounesA , GopalAK , SmithSE , AnsellSM , RosenblattJD , SavageKJ , et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology2012;30(18):2183‐9. [PUBMED: 22454421] ">Younes 2012</a>). Chen and colleagues reported an OS rate of 41% and PFS rate of 22% at five years in 102 participants who had failed haematopoietic ASCT and received brentuximab vedotin (<a href="./references#CD012556-bbs2-0031" title="ChenR , GopalAK , SmithSE , AnsellSM , RosenblattJD , SavageKJ , et al. Five‐year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood2016;128(12):1562‐6. [PUBMED: 27432875] ">Chen 2016</a>). However, most participants eventually become refractory to brentuximab vedotin, with limited treatment options. </p> </section> <section id="CD012556-sec-0025"> <h3 class="title" id="CD012556-sec-0025">Description of the intervention</h3> <p>The European Medicines Agency (EMA) approved nivolumab for the treatment of people with relapsed/refractory cHL after ASCT and treatment with brentuximab vedotin in October 2016. The approval was based on an objective response rate (ORR) of 66% in a combined analysis of 95 participants with relapsed or refractory cHL who received nivolumab either in the phase II CheckMate‐205 trial or the phase I CheckMate‐039 trial (<a href="./references#CD012556-bbs2-0024" title="AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):311‐9. ">Ansell 2015</a>; <a href="./references#CD012556-bbs2-0072" title="YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. ">Younes 2016</a>). The 12‐month PFS was 54.6% and 12‐month overall survival (OS) was 94.9% (<a href="./references#CD012556-bbs2-0069" title="TimmermanJ , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128:1110. ">Timmermann 2016</a>). </p> <p>The most common drug‐related adverse events (AEs) include fatigue, infusion‐related reaction, arthralgia and rash. The most common drug‐related grade 3 or 4 AEs were neutropenia and increased lipase concentrations. The most common serious adverse events (SAEs) include fever and meningitis (4% or less each) (<a href="./references#CD012556-bbs2-0069" title="TimmermanJ , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128:1110. ">Timmermann 2016</a>; <a href="./references#CD012556-bbs2-0072" title="YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. ">Younes 2016</a>). </p> <p>Nivolumab is now also used in combination with other drugs to treat people with relapsed or refractory HL (<a href="./references#CD012556-bbs2-0025" title="AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). 58th ASH Annual Meeting; Dec 3‐6; San Diego (CA). 2016. ">Ansell 2016</a>). </p> </section> <section id="CD012556-sec-0026"> <h3 class="title" id="CD012556-sec-0026">How the intervention might work</h3> <p>Checkpoint inhibitors that target the interaction of the programmed death (PD)‐1 immune checkpoint receptor, and its ligands PD‐L1 and PD‐L2, have shown remarkable activity in a wide range of malignancies. Development started in solid tumours and is most advanced in malignant melanoma and lung cancer (<a href="./references#CD012556-bbs2-0027" title="BrahmerJ , ReckampKL , BaasP , CrinòL , EberhardtWE , PoddubskayaE , et al. Nivolumab versus docetaxel in advanced squamous‐cell non‐small‐cell lung cancer. New England Journal of Medicine2015;373(2):123‐35. [PUBMED: 26028407] ">Brahmer 2015</a>; <a href="./references#CD012556-bbs2-0042" title="HamidO , RobertC , DaudA , HodiFS , HwuWJ , KeffordR , et al. Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. New England Journal of Medicine2013;369(2):134‐44. [PUBMED: 23724846] ">Hamid 2013</a>). In cHL, malignant Hodgkin Reed‐Sternberg (HRS) cells are dispersed within an extensive inflammatory/immune cell infiltrate (<a href="./references#CD012556-bbs2-0046" title="KüppersR . The biology of Hodgkin's lymphoma. Nature Reviews. Cancer2009;9(1):15‐27. [PUBMED: 19078975] ">Küppers 2009</a>; <a href="./references#CD012556-bbs2-0050" title="MathasS , HartmannS , KüppersR . Hodgkin lymphoma: Pathology and biology. Seminars in Hematology2016;53(3):139‐47. [PUBMED: 27496304] ">Mathas 2016</a>). HRS cells frequently overexpress PD‐L1 and PD‐L2 due to alterations in chromosome 9p24.1 and HL tumours may thus be genetically susceptible to blockade of the PD‐1 pathway (<a href="./references#CD012556-bbs2-0041" title="GreenMR , RodigS , JuszczynskiP , OuyangJ , SinhaP , O'DonnellE , et al. Constitutive AP‐1 activity and EBV infection induce PD‐L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical Cancer Research2012;18(6):1611‐8. [PUBMED: 22271878] ">Green 2012</a>; <a href="./references#CD012556-bbs2-0060" title="RoemerMG , AdvaniRH , LigonAH , NatkunamY , ReddRA , HomerH , et al. PD‐L1 and PD‐L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. Journal of Clinical Oncology2016;34(23):2690‐7. [PUBMED: 27069084] ">Roemer 2016</a>). Nivolumab is an anti‐(PD)‐1 monoclonal antibody and currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma, non‐small cell lung cancer, renal cell carcinoma (<a href="./references#CD012556-bbs2-0051" title="MatsukiE , YounesA . Checkpoint inhibitors and other immune therapies for Hodgkin and non‐Hodgkin lymphoma. Current Treatment Options in Oncology2016;17(6):31. ">Matsuki 2016</a>), and, since 2016, cHL after treatment with ASCT and brentuximab vedotin. </p> </section> <section id="CD012556-sec-0027"> <h3 class="title" id="CD012556-sec-0027">Why it is important to do this review</h3> <p>To our knowledge, no systematic review on the effectiveness of nivolumab in people with HL has been performed. As nivolumab is now approved by the EMA and the FDA based on non‐randomised data, we critically appraised all published trials and conducted this rapid review on nivolumab. If we identify controlled clinical trials in a future update, we will meta‐analyse these data, which will lead to a more precise and reliable evaluation of the benefits and harms of nivolumab. In this way, we aim to overcome the limitations of individual studies, such as small sample sizes and a lack of statistical power. </p> <p>For this review, we used the software RobotReviewer to extract study data (<a href="./references#CD012556-bbs2-0049" title="MarshallIJ , KuiperJ , WallaceB C . RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials. Journal of the American Medical Informatics Association2016;23(1):193‐201. ">Marshall 2016</a>; <a href="./references#CD012556-bbs2-0059" title="MarshallIJ , KuiperJ , WallaceBC . RobotReviewer. Version accessed February 2017 2015. Available at www.robotreviewer.net. ">RobotReviewer 2015</a>). For review updates including randomised controlled trials (RCT), we will use this software also to assess risk of bias. As this software has not been not validated, one review author will extract all these data manually and a second review author will compare the results from the software tool and the first review author. We will resolve any discrepancies between the software results and the manually extracted data by discussion between review authors. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012556-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-sec-0135">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012556-sec-0028"></div> <p>To assess the benefits and harms of nivolumab in adults with HL (irrespective of stage of disease). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012556-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-sec-0136">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012556-sec-0029"></div> <section id="CD012556-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012556-sec-0031"> <h4 class="title">Types of studies</h4> <p>We searched for RCTs. As we did not identify any RCTs or quasi‐RCTs (e.g. assignment to treatment by alternation or by date of birth) or cross‐over trials, we included published reports of prospectively planned studies. </p> <p>We included both full‐text and abstract publications if sufficient information was available on study design, characteristics of participants, interventions and outcomes. </p> </section> <section id="CD012556-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies that evaluated adults of 18 years or more with a confirmed diagnosis of HL, with no gender or ethnicity restrictions. We considered people with all subtypes and stages of HL, undergoing first‐line treatment, or having relapsed, or being refractory to previous treatment attempts. In trials that included mixed populations of participants with haematological malignancies, we would have included data from participants with HL; however, we did not identify such a trial. We excluded trials in which less than 80% of participants had HL, unless the trial authors provided the subgroup data for these participants in the publication or after we contacted the trial authors. </p> </section> <section id="CD012556-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The experimental intervention was nivolumab (with or without other drugs). If we identify RCTs in future updates of this review, the comparison of interest will be nivolumab (with or without other drugs) versus control treatment. We will conduct separate analyses for trials that evaluate nivolumab and nivolumab combined with other drugs. </p> </section> <section id="CD012556-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD012556-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012556-list-0001"> <li> <p>Overall survival (OS).</p> </li> <li> <p>Quality of life (QoL), if measured using reliable and valid instruments.</p> </li> </ul> </p> </section> <section id="CD012556-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012556-list-0002"> <li> <p>Progression‐free survival (PFS):</p> <ul id="CD012556-list-0003"> <li> <p>time interval from random treatment assignment onto the study to first confirmed progression, relapse or death from any cause, or to the last follow‐up. </p> </li> </ul> </li> <li> <p>Response rate:</p> <ul id="CD012556-list-0004"> <li> <p>measured as overall response, complete response and partial response according to Cheson and colleagues (<a href="./references#CD012556-bbs2-0032" title="ChesonBD , FisherRI , BarringtonSF , CavalliF , SchwartzLH , ZuccaE , et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology2014;32(27):3059‐68. [PUBMED: 25113753] ">Cheson 2014</a>). </p> </li> </ul> </li> <li> <p>Treatment‐related mortality (TRM).</p> </li> <li> <p>Overall rate of grade 3 and grade 4 adverse events (AEs), including potential relationship between intervention and adverse reactions. </p> </li> <li> <p>Overall rate of serious adverse events (SAEs).</p> </li> </ul> </p> </section> </section> </section> <section id="CD012556-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We adapted search strategies from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012556-bbs2-0047" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We searched for studies in all languages to limit language bias. </p> <section id="CD012556-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases and sources and started the search in 2000 as PD‐L1 blockade for tumour control, the underlying mechanism of nivolumab, was first mentioned in 2002 (<a href="./references#CD012556-bbs2-0045" title="IwaiY , IshidaM , TanakaY , OkazakiT , HonjoT , MinatoN . Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade. Proceedings of the National Academy of Sciences of the United States of America2002;99(19):12293‐7. ">Iwai 2002</a>). </p> <p> <ul id="CD012556-list-0005"> <li> <p>Databases of medical literature:</p> <ul id="CD012556-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018 Issue 5) (<a href="./appendices#CD012556-sec-0099">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (Ovid) (2000 to 13 April 2018) (<a href="./appendices#CD012556-sec-0100">Appendix 2</a>); </p> </li> <li> <p>Embase (2000 to October 2017) (<a href="./appendices#CD012556-sec-0101">Appendix 3</a>); </p> </li> <li> <p>International Pharmaceutical Abstracts (2000 to October 2017) (<a href="./appendices#CD012556-sec-0102">Appendix 4</a>). </p> </li> </ul> </li> <li> <p>Conference proceedings of the annual meetings of the following societies for abstracts (2000 to May 2018, if not included in CENTRAL): </p> <ul id="CD012556-list-0007"> <li> <p>American Society of Hematology;</p> </li> <li> <p>American Society of Clinical Oncology;</p> </li> <li> <p>European Hematology Association;</p> </li> <li> <p>International Symposium on Hodgkin Lymphoma.</p> </li> </ul> </li> <li> <p>Databases of ongoing trials:</p> <ul id="CD012556-list-0008"> <li> <p>ISRCTN: <a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>; </p> </li> <li> <p>EU clinical trials register: <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">www.clinicaltrialsregister.eu/ctr‐search/search</a> (<a href="./appendices#CD012556-sec-0103">Appendix 5</a>); </p> </li> <li> <p>ClinicalTrials.gov: <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a> (<a href="./appendices#CD012556-sec-0104">Appendix 6</a>); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP): <a href="http://apps.who.int/trialsearch/AdvSearch.aspx" target="_blank">apps.who.int/trialsearch/AdvSearch.aspx</a> (<a href="./appendices#CD012556-sec-0105">Appendix 7</a>); </p> </li> <li> <p>EORTC: <a href="http://www.eortc.be" target="_blank">www.eortc.be</a>; </p> </li> <li> <p>GHSG: <a href="http://www.ghsg.org" target="_blank">www.ghsg.org</a>. </p> </li> </ul> </li> <li> <p>Databases and websites of relevant institutions, such as pharmaceutical organisations, agencies and societies. </p> </li> </ul> </p> </section> <section id="CD012556-sec-0039"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD012556-list-0009"> <li> <p>Handsearching:</p> <ul id="CD012556-list-0010"> <li> <p>we checked the reference lists of all identified trials, relevant review articles and current treatment guidelines for further literature. </p> </li> </ul> </li> <li> <p>Personal contacts:</p> <ul id="CD012556-list-0011"> <li> <p>we contacted experts in the field, drug manufacturers and regulatory agencies to retrieve information on unpublished trials. </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD012556-sec-0040"> <h3 class="title" id="CD012556-sec-0040">Data collection and analysis</h3> <section id="CD012556-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the results of the search strategies for eligibility for this review by reading the abstracts using Covidence software (<a href="./references#CD012556-bbs2-0034" title="Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, Available at www.covidence.org. ">Covidence 2016</a>). We coded the abstracts as either 'retrieve' or 'do not retrieve.' In the case of disagreement or if it was unclear whether we should retrieve the abstract or not, we obtained the full‐text publication for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach a consensus, we consulted a third review author to reach final decision (<a href="./references#CD012556-bbs2-0043" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p>We documented the study selection process in a flow chart, as recommended in the PRISMA statement (<a href="./references#CD012556-bbs2-0052" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>), and showed the total numbers of retrieved references and the numbers of included and excluded studies. We listed all articles we excluded after full‐text assessment and their reasons for exclusion in the <a href="./references#CD012556-sec-0128" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD012556-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We planned that one review author extracted data on the characteristics of included studies and a second review author compared them with the results from the software RobotReviewer (<a href="./references#CD012556-bbs2-0049" title="MarshallIJ , KuiperJ , WallaceB C . RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials. Journal of the American Medical Informatics Association2016;23(1):193‐201. ">Marshall 2016</a>; <a href="./references#CD012556-bbs2-0059" title="MarshallIJ , KuiperJ , WallaceBC . RobotReviewer. Version accessed February 2017 2015. Available at www.robotreviewer.net. ">RobotReviewer 2015</a>). However, as we identified no eligible RCTs and the software is currently designed to extract RCTs, two review authors (MG and NS) additionally extracted data independently. The two review authors resolved any discrepancies by discussion; had they not reached consensus, they planned to consult a third review author, but this was not necessary. If required, they would have contacted the authors of specific studies for supplementary information (<a href="./references#CD012556-bbs2-0044" title="HigginsJP , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p>We extracted the following information.</p> <p> <ul id="CD012556-list-0012"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Quality assessment (as specified in the <a href="#CD012556-sec-0043">Assessment of risk of bias in included studies</a> section). </p> </li> <li> <p>Study characteristics: trial design, aims, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, subgroup analysis, statistical methods, power calculations, treatment cross‐overs, compliance with assigned treatment, length of follow‐up. </p> </li> <li> <p>Participant characteristics: age, gender, ethnicity, number of participants recruited/allocated/evaluated, participants lost to follow‐up, additional diagnoses, stage of disease, previous treatment (type of (multi‐agent) chemotherapy (intensity of regimen, number of cycles), field and dose of radiotherapy, ASCT, brentuximab vedotin dosage and duration). </p> </li> <li> <p>Interventions: nivolumab dosage, duration of treatment, duration of follow‐up, for RCTs: comparator (type, dosage). </p> </li> <li> <p>Outcomes: OS, QoL, PFS, response rate, TRM, AEs (including assessment of causality, how it was determined, relation between intervention and adverse drug reaction, method of AEs ascertainment (passive or active methods), method of measurement, how severity or seriousness was measured). </p> </li> </ul> </p> </section> <section id="CD012556-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD012556-sec-0044"> <h5 class="title">Randomised controlled trials</h5> <p>If we identify RCTs for future updates, we will assess risk of bias with the Cochrane 'Risk of bias' tool for each RCT. Thereafter, we will use the RobotReviewer software to assess risk of bias (<a href="./references#CD012556-bbs2-0059" title="MarshallIJ , KuiperJ , WallaceBC . RobotReviewer. Version accessed February 2017 2015. Available at www.robotreviewer.net. ">RobotReviewer 2015</a>), and a second review author will compare these results with the results from the first review author. See <a href="#CD012556-sec-0124">Differences between protocol and review</a> for a more detailed description of the 'Risk of bias' assessment we will undertake if we identify eligible RCTs in future updates. </p> </section> <section id="CD012556-sec-0045"> <h5 class="title">Non‐randomised prospectively planned trials (including control arm)</h5> <p>As reported in the <a href="#CD012556-sec-0031">Types of studies</a> section, we would have included non‐randomised studies with a control arm only if we did not identify any RCTs. However, we did not identify any non‐randomised prospectively planned study with a control arm. If we identify non‐randomised studies with a control arm in review updates, we will independently assess eligible studies for methodological quality and risk of bias (using the Risk Of Bias in Non‐randomised Studies ‐ of Interventions (ROBIN‐I) tool) (<a href="./references#CD012556-bbs2-0066" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016;355:i4919. ">Sterne 2016</a>). </p> </section> <section id="CD012556-sec-0046"> <h5 class="title">Uncontrolled studies</h5> <p>As reported in the <a href="#CD012556-sec-0031">Types of studies</a> section, we included non‐randomised studies without a control arm only as we did not identify any RCTs. </p> <p>Two review authors independently assessed eligible studies for methodological quality and risk of bias (using the "risk of bias assessment criteria for observational studies" tool provided by the Childhood Cancer Group (see <a href="#CD012556-tbl-0002">Table 1</a>). The quality assessment strongly depends upon information on the design, conduct and analysis of the trial. The two review authors resolved any disagreements regarding the quality assessments by discussion, in case they would not have reached a consensus they would have consulted a third review author until final consensus. </p> <div class="table" id="CD012556-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>External validity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias</b> (representative: yes/no) </p> <p> <ul id="CD012556-list-0013"> <li> <p>if the described study group consisted of &gt; 80% of the Hodgkin's lymphoma participants treated with nivolumab in the original cohort </p> </li> </ul> </p> <p><b>or</b> </p> <p> <ul id="CD012556-list-0014"> <li> <p>if it was a random sample with respect to the cancer treatment and important prognostic factors </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0015"> <li> <p>if the mean/median or range of the cumulative nivolumab dose was mentioned</p> </li> </ul> </p> <p><b>and</b> </p> <p> <ul id="CD012556-list-0016"> <li> <p>when it was described what prior treatment (including the received doses) was given</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition bias</b> (adequate: yes/no) </p> <p> <ul id="CD012556-list-0017"> <li> <p><br/>if the outcome was assessed for &gt; 90% of the study group of interest (++) </p> </li> </ul> </p> <p><br/><b>or</b> </p> <p> <ul id="CD012556-list-0018"> <li> <p>if the outcome was assessed for 60‐90% of the study group of interest (+)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no)<br/></p> <p> <ul id="CD012556-list-0019"> <li> <p>if the length of follow‐up was mentioned</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detection bias</b> (blind: yes/no) </p> <p> <ul id="CD012556-list-0020"> <li> <p><br/>if the outcome assessors were blinded to the investigated determinant </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0021"> <li> <p><br/>if the outcome definition was objective and precise, and the method of detection was provided </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk estimation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confounding</b>(adjustment for other factors: yes/no) </p> <p> <ul id="CD012556-list-0022"> <li> <p>if important prognostic factors (i.e. age, gender, cotreatment) or follow‐up were taken adequately into account </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analyses</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0023"> <li> <p>if a risk ratio, odds ratio, attributable risk, linear or logistic regression model, mean difference or Chi<sup>2</sup> was calculated </p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> <p>We assessed the following domains of bias.</p> <p> <ul id="CD012556-list-0024"> <li> <p>Internal validity.</p> </li> </ul> <ul class="plain" id="CD012556-list-0025"> <li> <ul id="CD012556-list-0026"> <li> <p>Representative study group (selection bias).</p> </li> <li> <p>Complete outcome assessment/follow‐up (attrition bias).</p> </li> <li> <p>Outcome assessors blinded to investigated determinant (detection bias).</p> </li> <li> <p>Important prognostic factors or follow‐up taken adequately into account (confounding).</p> </li> </ul> </li> </ul> <ul id="CD012556-list-0027"> <li> <p>External validity.</p> </li> </ul> <ul class="plain" id="CD012556-list-0028"> <li> <ul id="CD012556-list-0029"> <li> <p>Well‐defined study group (reporting bias).</p> </li> <li> <p>Well‐defined follow‐up (reporting bias).</p> </li> <li> <p>Well‐defined outcome (reporting bias).</p> </li> <li> <p>Well‐defined risk estimates (analyses).</p> </li> </ul> </li> </ul> </p> <p>For every criterion, we made a judgement using one of three response options.</p> <p> <ul id="CD012556-list-0030"> <li> <p>High risk of bias.</p> </li> <li> <p>Low risk of bias.</p> </li> <li> <p>Unclear risk of bias.</p> </li> </ul> </p> </section> </section> <section id="CD012556-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>We estimated the dichotomous outcomes of individual studies as rates by extracting the number of events and the total number of participants (overall and complete response rate, TRM, AEs). </p> <p>We estimated survival data (OS, PFS) using Kaplan–Meier methods.</p> <p>We measured continuous outcomes (e.g. QoL) as mean differences (MD).</p> <p>In case we identify eligible RCTs in updates of this review, we will extract and report effect measures in accordance with the procedures outlines in the <a href="#CD012556-sec-0124">Differences between protocol and review</a> section. </p> </section> <section id="CD012556-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012556-sec-0049"> <h5 class="title">Studies with multiple treatment groups</h5> <p>We did not identify any eligible studies with multiple treatment groups. We described how we will proceed with such studies in review updates in the <a href="#CD012556-sec-0124">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD012556-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests a number of potential sources for missing data (<a href="./references#CD012556-bbs2-0043" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), which we needed to take into account at study level, at outcome level and at summary data level. In the first instance, it is of the utmost importance to differentiate between data 'missing at random' and 'not missing at random.' </p> <p>If data have been missing, we would have requested these data from the original investigators. If, after this, data were still missing, we would have to make explicit assumptions of any methods the included studies used: for example, we would have assumed that the data were missing at random or we would have assumed that missing values had a particular value, such as a poor outcome. </p> </section> <section id="CD012556-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>If we find sufficient data for meta‐analysis in updates of this review, we will assess potential heterogeneity as described in <a href="./appendices#CD012556-sec-0106">Appendix 8</a>. </p> </section> <section id="CD012556-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>In updates of this review where a meta‐analysis is feasible, we will assess potential reporting biases in accordance with the methods described in <a href="./appendices#CD012556-sec-0106">Appendix 8</a>. </p> </section> <section id="CD012556-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We did not meta‐analyse data from the included uncontrolled trials, as there might be no additional benefit in meta‐analysing data without a control group. We reported results of each included trial. As data did not allow quantitative assessment, we presented outcome data individually per study (see <a href="./references#CD012556-sec-0127" title="">Characteristics of included studies</a> table). In further updates of this review we will meta‐analyse data in accordance with the procedure described in <a href="./appendices#CD012556-sec-0106">Appendix 8</a>. </p> <section id="CD012556-sec-0054"> <h5 class="title">'Summary of findings' table</h5> <p>We used the GRADE approach to assess the quality of the evidence. We used GRADEpro Guideline Development Tool (GDT) software to create a 'Summary of findings' table (<a href="./references#CD012556-bbs2-0040" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed February 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>), as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012556-bbs2-0062" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings tables'. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). In addition, we provided an interactive 'Summary of findings' table for a better user‐experience and for improved dissemination of the findings of this Cochrane Review (<a href="./references#CD012556-bbs2-0063" title="SchünemannHJ , MustafaR , BrozekJ , SantessoN , Alonso‐CoelloP , GuyattG , et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology2016;76:89‐98. ">Schünemann 2016</a>). We avoided use of lengthy text in the results and discussion section. </p> <p>We prioritised outcomes according to their relevance to people with HL.</p> <p> <ul id="CD012556-list-0031"> <li> <p>OS.</p> </li> <li> <p>QoL.</p> </li> <li> <p>PFS.</p> </li> <li> <p>Response rates.</p> </li> <li> <p>TRM.</p> </li> <li> <p>AEs.</p> </li> <li> <p>SAEs.</p> </li> </ul> </p> <p>Since all included studies were uncontrolled studies, the certainty of the evidence for all outcomes started at "low certainty" (2 points) </p> </section> </section> <section id="CD012556-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For future updates including meta‐analyses, we will perform subgroup analyses following the procedure described in <a href="./appendices#CD012556-sec-0106">Appendix 8</a>. </p> </section> <section id="CD012556-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>For future updates including meta‐analyses, we will perform sensitivity analyses according to the methods described in <a href="./appendices#CD012556-sec-0106">Appendix 8</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012556-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012556-sec-0057"></div> <section id="CD012556-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD012556-sec-0059"> <h4 class="title">Results of the search</h4> <p>We identified 782 potentially relevant references. At the initial screening stage, we excluded 107 duplicates and 626 reference due to a lack of conformity with the inclusion criteria. We further evaluated the remaining 49 publications either as full‐text publications or, if not available, as abstract publications or study registry entry. This led to exclusion of five further trials. In addition, we identified 14 ongoing trials (18 references), which will be completed by 2021, two studies (five references) studies already reported interim results for some of the included participants (<a href="./references#CD012556-bbs2-0010" title="DiefenbachCS , HongF , DavidK , CohenJ , RoberstonM , AdvaniR , et al. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Hematological Oncology2017;35:84‐5. DiefenbachCS , HongF , DavidKA , CohenJ , RobertsonM , AdvaniR , et al. A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412 Arms D and E). Blood2016;128(22):1106. DiefenbachCSM , HongF , AmbinderRF , CohenJB , RobertsonMJ , FenskeTS , et al. A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Haematologica2016;101:44‐5. ">NCT01896999</a>; <a href="./references#CD012556-bbs2-0012" title="HerreraAF , BartlettNL , RamchandrenR , VoseJM , MoskowitzAJ , FeldmanTA , et al. Preliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood2016;128(22):1105. HerreraAF , MoskowitzAJ , BartlettNL , VoseJM , RamchandrenR , FeldmanTA , et al. Interim results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Hematological Oncology2017;35:85‐6. HerreraAF , MoskowitzAJ , BartlettNL , VoseJM , RamchandrenR , FeldmanTA , et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood2018;131(11):1183‐94. ">NCT02572167</a>). Only two of these ongoing trials are RCTs (<a href="./references#CD012556-bbs2-0017" title="Nivolumab and AVD in early‐stage unfavourable classical Hodgkin lymphoma (NIVAHL). Ongoing study 21 February 2017; estimated primary completion date: December 2018 (final data collection date for primary outcome). ">NCT03004833</a>; <a href="./references#CD012556-bbs2-0021" title="A study of nivolumab plus brentuximab vedotin versus brentuximab vedotin alone in patients with advanced stage classical Hodgkin lymphoma, who are relapsed/ refractory or who are not eligible for autologous stem cell transplant (CheckMate 812). Ongoing study 16 May 2017; estimated primary completion date: 29 November 2020 (final data collection date for primary outcome). ">NCT03138499</a>). We finally included three studies (26 references) in this systematic review. </p> <p>We reported the overall numbers of references screened, identified, selected, excluded and included in a PRISMA flow diagram (see <a href="#CD012556-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012556-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012556-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD012556-sec-0060"> <h5 class="title">Results of the application of RobotReviewer</h5> <p>Although our search did not identify any eligible RCTs, we uploaded available full‐texts of the three included studies into the software RobotReviewer. The software recognised correctly that one study was not an RCT and therefore did not extract any data of this study. However, the two remaining studies were falsely labelled to be RCTs. The extraction results on both studies could not be used in the further review process. Yet some characteristics of included trials were given sufficiently. This is especially concerning the data regarding included participants and study interventions. We did not consider the 'Risk of bias' function of the software, since it was based on the criteria of the Cochrane 'Risk of bias' tool for RCTs only. </p> </section> </section> <section id="CD012556-sec-0061"> <h4 class="title">Included studies</h4> <p>For detailed description of the studies see the <a href="./references#CD012556-sec-0127" title="">Characteristics of included studies</a> table. Here we provided a brief overview. </p> <p>Three prospectively planned, uncontrolled trials evaluated the effect and safety of nivolumab in people with HL (283 participants) (<a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a>; <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a>; <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>). All of these trials included heavily pretreated participants and were published as full‐texts. </p> <section id="CD012556-sec-0062"> <h5 class="title">Design</h5> <p><a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> was a phase I trial, <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> and <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> were phase II trials. Follow‐up ranged between 12 months and 23 months. </p> </section> <section id="CD012556-sec-0063"> <h5 class="title">Sample sizes</h5> <p>The smallest trial involved 17 people with HL (<a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>), <a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> involved 23 participants and <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> involved 243 participants. </p> </section> <section id="CD012556-sec-0064"> <h5 class="title">Location</h5> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> was conducted in Japan and the other two trials were in several countries in US, Europe and Canada. </p> </section> <section id="CD012556-sec-0065"> <h5 class="title">Participants</h5> <p>All trials included adults with at least one prior chemotherapy regimen.</p> <p><a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> evaluated participants with relapsed or refractory HL with at least one prior chemotherapy regimen. The mean age was 35 years. </p> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> included adults after failure of ASCT. It had three cohorts: cohort A had 63 people with cHL after failure of ASCT, cohort B had 80 people with cHL after failure of ASCT who received subsequent brentuximab vedotin and cohort C had 100 people with cHL after failure of ASCT who had previous or subsequent brentuximab vedotin treatment (or both). The mean age was 34 years. </p> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> evaluated participants with history of treatment with ASCT, people to whom ASCT was not indicated or who refused to receive treatment with ASCT. The mean age was 63 years. </p> </section> <section id="CD012556-sec-0066"> <h5 class="title">Interventions</h5> <p><a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a>: consisted of a dose escalation cohort and an expansion cohort. The dose escalation cohort (phase I trial) received nivolumab 1 mg/kg bodyweight with escalation to 3 mg/kg. With 3 mg/kg as the final dose, the maximum tolerated dose leading to dose‐limiting toxicities was not reached in this phase I trial with a preset fixed‐dose escalation plan. The expansion cohort received nivolumab 3 mg/kg at week one, week four, and then every two weeks until disease progression or complete response for a maximum of two years. </p> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a>: participants received nivolumab 3 mg/kg intravenously over 60 minutes every two weeks until disease progression, death, unacceptable toxicity, withdrawal of consent or study end (five years or more of follow‐up). </p> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>: participants received nivolumab 3 mg/kg on day one of the treatment phase; subsequent doses were administered on day one of each 14‐day cycle. Nivolumab was continued if treatment continuation criteria were met; trial was to continue until all participants discontinued treatment in the event of progressive disease, an unacceptable AE or other clinically relevant reasons, so trial participants are still under investigation. </p> </section> <section id="CD012556-sec-0067"> <h5 class="title">Outcomes</h5> <p>The primary outcomes were:</p> <p> <ul id="CD012556-list-0032"> <li> <p>proportion of participants achieving an objective response;</p> </li> <li> <p>overall response rate;</p> </li> <li> <p>safety.</p> </li> </ul> </p> <p>The secondary outcomes were:</p> <p> <ul id="CD012556-list-0033"> <li> <p>duration of response outcomes;</p> </li> <li> <p>proportion of participants who achieved response;</p> </li> <li> <p>PFS;</p> </li> <li> <p>OS;</p> </li> <li> <p>safety and tolerability;</p> </li> <li> <p>QoL;</p> </li> <li> <p>safety endpoints;</p> </li> </ul> </p> </section> <section id="CD012556-sec-0068"> <h5 class="title">Conflicts of interest</h5> <p>Bristol‐Myers Squibb funded the <a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> and <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> trials and Ono Pharmaceutical Co., Ltd. funded <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>, which are the pharmaceutical companies producing nivolumab. </p> </section> </section> <section id="CD012556-sec-0069"> <h4 class="title">Excluded studies</h4> <p>After screening of titles/abstracts we excluded 561 records that did not match our inclusion criteria. We evaluated five study reports in more detail, which were finally excluded: three trials were not prospectively planned, one study evaluated people with non‐HL only and one report was a case report (see <a href="./references#CD012556-sec-0128" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD012556-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, we considered potential risk of bias as high, due to the non‐randomised study design, the unblinded outcome assessment and the absence of a control group. For further information, see the 'Risk of bias' sections in the <a href="./references#CD012556-sec-0127" title="">Characteristics of included studies</a> table and <a href="#CD012556-fig-0002">Figure 2</a> ('Risk of bias' summary figure presenting all our judgements in a cross‐tabulation). </p> <div class="figure" id="CD012556-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012556-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012556-sec-0071"> <h4 class="title">Internal validity</h4> <section id="CD012556-sec-0072"> <h5 class="title">Representative study group (selection bias)</h5> <p>All trials were non‐randomised with no control arm. As selection bias was not assessable in this type of trial, we judged risk of selection bias as unclear. However, recurrent cHL was an inclusion criterion in all included studies. </p> </section> <section id="CD012556-sec-0073"> <h5 class="title">Complete outcome assessment/follow‐up (attrition bias)</h5> <p>We judged the risk of attrition bias to be low because the analyses reported results for all included participants. </p> <p>For QoL, given for a subset of participants (cohort B) in <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a>, follow‐up data for only 44/80 participants were available. Therefore, we judged the risk of bias for QoL to be high. </p> </section> <section id="CD012556-sec-0074"> <h5 class="title">Outcome assessors blinded to investigated determinant (detection bias)</h5> <p>Two trials did not blind outcome assessors (<a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a>; <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>) (potential high risk of bias) and one study had unclear blinding (<a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a>). For OS, lack of blinding was not an issue, therefore we judged risk of bias for OS as low. </p> </section> <section id="CD012556-sec-0075"> <h5 class="title">Important prognostic factors or follow‐up taken adequately into account (confounding)</h5> <p>All included trials reported previous treatments with ASCT and BV. <a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> and <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> separately reported clinical activity results for participants in whom previous ASCT and BV failed, participants in whom BV failed who did not undergo ASCT and participants who did not receive ASCT. However, no multi‐variable analyses taking into account important prognostic factors like pretreatments, participant age or the length of follow‐up were reported. Therefore, we judged the risk of bias due to confounding to be high. </p> </section> </section> <section id="CD012556-sec-0076"> <h4 class="title">External validity</h4> <p>We considered the risk of reporting bias as high related to the criterion well‐defined study groups, as all trials included heterogenous participant populations and they did not report doses for the received pretreatments. </p> <p>Follow‐up data, outcome reporting and the methods used for risk‐estimation were well‐defined, therefore we judged these criteria for all trials as low risk of bias. </p> </section> </section> <section id="CD012556-sec-0077"> <h3 class="title" id="CD012556-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD012556-tbl-0001"><b>Summary of findings for the main comparison</b> Nivolumab compared to no other intervention for adults with Hodgkin's lymphomas</a> </p> <section id="CD012556-sec-0078"> <h4 class="title">Primary outcome: overall survival</h4> <p>Two studies evaluated OS. <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> reported that median OS was not reached after a median follow‐up of 18 months (interquartile range (IQR) 15 to 22 months) for the overall study population, meaning that more than 50% of participants are still alive. The one‐year OS was 92% (95% confidence interval (CI) 88% to 95%) for the overall study population; 93% (95% CI 82% to 98%) for cohort A (63 participants with cHL after failure of ASCT); 95% (95% CI 87% to 98%) for cohort B (80 participants with cHL after failure of ASCT and subsequent brentuximab vedotin treatment); and 90% (95% CI 82% to 94%) for cohort C (100 participants with cHL after failure of ASCT, and previous or subsequent (or both) brentuximab vedotin treatment). <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> reported 100% OS after six months. </p> <section id="CD012556-sec-0079"> <h5 class="title">Overall survival in participants not treated with nivolumab</h5> <p><a href="./references#CD012556-bbs2-0028" title="BroeckelmannP , MuellerH , KücüksarioglanE , KaskelP , MetterleinV , GiezeckH , et al. Clinical outcomes of patients with 3rd or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. Blood2017;130(Suppl 1):2793‐93. ">Broeckelmann 2017</a> was a retrospective analysis of people with third or higher relapsed/refractory cHL, <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> had a median number of previous chemotherapy regimens of four and <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> had a median number of previous chemotherapy regimens of three. OS was 73.2% (95% CI 62.6 to 83.8) at 12 months for all participants. In <a href="./references#CD012556-bbs2-0028" title="BroeckelmannP , MuellerH , KücüksarioglanE , KaskelP , MetterleinV , GiezeckH , et al. Clinical outcomes of patients with 3rd or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. Blood2017;130(Suppl 1):2793‐93. ">Broeckelmann 2017</a>, participants with third relapse who underwent previous ASCT had an OS of 69.4% (95% CI 56.5% to 82.3%) at 12 months. The OS of participants who had a third relapse who did not receive ASCT was 62.5% (95% CI 29.0% to 96.0%) at 12 months. The OS at six months for both groups was 89.6% (95% CI 82.4% to 96.9%), in contrast to 100% in <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a>. </p> </section> </section> <section id="CD012556-sec-0080"> <h4 class="title">Primary outcome: quality of life</h4> <p>Only one of the three cohorts of <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> (cohort B, 80 participants with cHL after failure of ASCT and subsequent brentuximab vedotin treatment) reported QoL using the EQ‐5D visual analogue scale (developed by the EuroQol Group; <a href="./references#CD012556-bbs2-0029" title="BrooksR . EuroQol: the current state of play. Health Policy (Amsterdam, Netherlands)1996;37(1):53‐72. [PUBMED: 10158943] ">Brooks 1996</a>), and the EORTC QLQ‐C30 (developed by EORTC to measure QoL; <a href="./references#CD012556-bbs2-0023" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365‐76. [PUBMED: 8433390] ">Aaronson 1993</a>). The scores increased over time with nivolumab treatment, indicating improved QoL (EQ‐5D: from 62 (standard deviation (SD) 30) at baseline (72 (90%) participants) to 80 (SD 18) at week 33 (44 (55%) participants); EORTC QLQ‐C30 suggested improvement from baseline across functional, symptom and global health scores). However, at week 33 only a subset of the included participants filled out the instruments. </p> </section> <section id="CD012556-sec-0081"> <h4 class="title">Secondary outcome: progression‐free survival</h4> <p>All trials reported PFS. <a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> published an investigator‐assessed PFS at six months of 86% (95% CI 62% to 95%). The overall PFS in <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> was 14.7 (95% CI 11.3 to 18.5). The study also reported data for the three cohorts (A: 63 participants with cHL after failure of ASCT, B: 80 participants with cHL after failure of ASCT and subsequent brentuximab vedotin treatment, C: 100 participants with cHL after failure of ASCT, and previous or subsequent (or both) brentuximab vedotin treatment). The median PFS was 18.3 months (95% CI 11.1 to 22.4) for cohort A, 14.7 months (95% CI 10.5 to 19.6) for cohort B and 11.9 months (95% CI 11.1 to 18.4) for cohort C. </p> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> presented a centrally assessed PFS at six months of 60% (95% CI 31.8% to 79.7%). </p> <section id="CD012556-sec-0082"> <h5 class="title">Progression‐free survival in participants not treated with nivolumab</h5> <p>The retrospective analysis of participants with third or higher relapse of cHL showed a six‐month PFS of 76.3% (95% CI 66.1% to 86.4%) for all included participants (<a href="./references#CD012556-bbs2-0028" title="BroeckelmannP , MuellerH , KücüksarioglanE , KaskelP , MetterleinV , GiezeckH , et al. Clinical outcomes of patients with 3rd or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. Blood2017;130(Suppl 1):2793‐93. ">Broeckelmann 2017</a>). The PFS at 12 months' follow‐up was 50.8% (95% CI 38.9% to 62.8%). The 12‐month PFS for participants with a third relapse and previous ASCT was 44.9% (95% CI 31.0% to 58.8%) and for participants with third relapse and without ASCT was 50.0% (95% CI 15.4% to 84.6%). </p> </section> </section> <section id="CD012556-sec-0083"> <h4 class="title">Secondary outcome: response rate</h4> <p><a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> reported a complete response rate of 17% and a partial response rate of 70% at median follow‐up of 86 weeks (range 32 to 107 weeks). </p> <p>In <a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a>, the median duration of response overall was 16.6 months (95% CI 13.2 to 20.3). For cohorts A it was 20.3 months, for cohort B it was 15.9 months and for cohort C it was 14.5 months. Overall, the complete response rate was 16%, while 29% of participants received complete response in cohort A, 13% in cohort B and 12% in cohort C. There was a partial response in 53% of participants overall and 37% of participants in cohort A, 55% of participants in cohort B and 61% of participants in cohort C. </p> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> reported for a centrally assessed response (one participant ineligible) a complete response rate of 25% and a partial response of 56.3% at a median follow‐up of 9.8 months (range 6 to 11 months). </p> </section> <section id="CD012556-sec-0084"> <h4 class="title">Secondary outcome: treatment‐related mortality</h4> <p>None of the trials reported TRM.</p> </section> <section id="CD012556-sec-0085"> <h4 class="title">Secondary outcome: overall rate of grade 3 and grade 4 adverse events, including potential relationship between intervention and adverse reaction </h4> <p><a href="./references#CD012556-bbs2-0001" title="AnsellS , ArmandP , TimmermanJ , ShippM , Popa McKiverM , ZhuL , et al. Nivolumab re‐treatment in patients with relapsed/refractory Hodgkin lymphoma: safety and efficacy outcomes from a phase 1 clinical trial. Haematologica. 2016; Vol. 101:49. AnsellS , ArmandP , TimmermanJM , ShippMA , GarelikMBB , ZhuL , et al. Nivolumab in patients (PTS) with relapsed or refractory classical Hodgkin lymphoma (R/R Chl): clinical outcomes from extended follow‐up of a phase 1 study (CA209‐039). Blood. 2015; Vol. 126, issue 23:583. AnsellS , GutierrezME , ShippMA , GladstoneD , MoskowitzA , BorelloI , et al. A phase 1 study of nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016; Vol. 128, issue 22:183. AnsellSM , LesokhinAM , BorrelloI , HalwaniA , ScottEC , GutierrezM , et al. PD‐1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine2015;372(4):308‐9. ArmandP , AnsellSM , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma‐preliminary safety, efficacy and biomarker results of a phase I study. Blood. 2014; Vol. 124:21. ArmandP , TimmermanJ , LesokhinA , HalwaniA , MillensonM , SchusterS , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (CA209‐039). Haematologica. 2015; Vol. 100:323. LesokhinAM , AnsellSM , ArmandP , ScottEC , HalwaniA , GutierrezM , et al. Preliminary results of a phase I study of nivolumab (BMS‐936558) in patients with relapsed or refractory lymphoid malignancies. Blood. 2014; Vol. 124:21. LesokhinAM , GutierrezM , HalwaniAS , AnsellSM , ArmandP , BorrelloI , et al. A phase I dose‐escalation study evaluating the effects of nivolumab (anti‐PD‐1; BMS‐936558; ONO‐4538) in patients (pts) with select relapsed or refractory hematologic malignancies. Journal of Clinical Oncology2013;31:15. TimmermanJ , ArmandP , LesokhinAM , HalwaniA , MillensonMM , SchusterSJ , et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase 1 study (CA209‐039). Hematological Oncology. 2015; Vol. 33:104‐5. ">CheckMate 039</a> reported at a median follow‐up of 86 weeks (range 32 to 107 weeks) 52% of grade 3 or 4 AEs. </p> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> reported drug‐related AEs only after a median follow‐up of 18 months (IQR 15 to 22 months). The most common drug‐related AEs were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%). The most common grade 3 to grade 4 drug‐related AEs for this follow‐up timeframe were lipase increases (5%), neutropenia (3%) and alanine transaminase increases (3%). </p> <p><a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> presented data at a median follow‐up of 9.8 months (range 6 to 11 months). Four of 17 (23.5%) participants developed grade 3 or 4 AEs. </p> </section> <section id="CD012556-sec-0086"> <h4 class="title">Secondary outcome: overall rate of serious adverse events</h4> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> reported only drug‐related SAEs. About 2% of participants had infusion reactions and 1% had pneumonitis. </p> <section id="CD012556-sec-0087"> <h5 class="title">Adverse events in participants not treated with nivolumab</h5> <p>Due to data deviations, the results of the studies included in this review could not be reasonably compared with those of the retrospective analysis (<a href="./references#CD012556-bbs2-0028" title="BroeckelmannP , MuellerH , KücüksarioglanE , KaskelP , MetterleinV , GiezeckH , et al. Clinical outcomes of patients with 3rd or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. Blood2017;130(Suppl 1):2793‐93. ">Broeckelmann 2017</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012556-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012556-sec-0088">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012556-sec-0164">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012556-sec-0088"></div> <section id="CD012556-sec-0089"> <h3 class="title" id="CD012556-sec-0089">Summary of main results</h3> <p>Although our search did not identify any eligible RCTs, we uploaded available full‐texts of the three included studies into the software RobotReviewer. The software recognised correctly that one study was not an RCT and, therefore, did not extract any data of this study. However, the two remaining studies were falsely labelled to be RCTs and characteristics of included study were extracted, in a sufficient way for types of participants and types of interventions. </p> <p>The following clinical findings emerged from this Cochrane Review in participants with heavily pretreated HL, for whom currently only three non‐randomised, uncontrolled trials were published (283 individuals). </p> <p> <ul id="CD012556-list-0034"> <li> <p>Median OS was not reached (the time point when only 50% of participants were alive) in one study after 12 months of follow‐up and was 100% in another trial after six months of follow‐up. </p> </li> <li> <p>Based on the currently available research, we were unable to draw any conclusions with regard to QoL as there were insufficient data available. </p> </li> <li> <p>PFS was between 60% and 86% at six months, median PFS between 11.9 and 18.3 months, depending on participant population and previous treatments. </p> </li> <li> <p>Complete response rates ranged from 12% to 29%, depending on inclusion criteria and participant characteristics. </p> </li> <li> <p>None of the trials reported TRM.</p> </li> <li> <p>Only one trial reported SAEs, with a low number of participants experiencing SAEs. Depending on follow‐up time, between 23% and 52% of participants developed grade 3 or 4 AEs. Most common were fatigue, diarrhoea, infusion reactions and rash. </p> </li> </ul> </p> <p>When interpreting these results, it is important to consider that RCTs are needed to confirm these findings. </p> </section> <section id="CD012556-sec-0090"> <h3 class="title" id="CD012556-sec-0090">Overall completeness and applicability of evidence</h3> <p>We found three published non‐randomised, uncontrolled trials evaluating nivolumab in adults with relapsed HL of whom most had received intensive therapies such as ASCT before. These trials included 283 participants who had received different therapeutic regimens before entering the trials. Therefore, the participant population might have been too small and heterogenous to generalise results. Currently, 14 trials are ongoing, of which two studies are designed as RCTs (one for participants receiving first‐line treatment, one for participants with relapsed HL) (<a href="./references#CD012556-bbs2-0009" title="Ipilimumab or nivolumab in treating adults with relapsed hematologic malignancies after donor stem cell transplant. Ongoing study 9 April 2013; planned primary completion date: 31 December 2018. ">NCT01822509</a>; <a href="./references#CD012556-bbs2-0010" title="DiefenbachCS , HongF , DavidK , CohenJ , RoberstonM , AdvaniR , et al. Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Hematological Oncology2017;35:84‐5. DiefenbachCS , HongF , DavidKA , CohenJ , RobertsonM , AdvaniR , et al. A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412 Arms D and E). Blood2016;128(22):1106. DiefenbachCSM , HongF , AmbinderRF , CohenJB , RobertsonMJ , FenskeTS , et al. A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG‐ACRIN Cancer Research Group (E4412). Haematologica2016;101:44‐5. ">NCT01896999</a>; <a href="./references#CD012556-bbs2-0011" title="Nivolumab and ipilimumab in treating adults with HIV associated relapsed or refractory classical Hodgkin's lymphoma or solid tumours that are metastatic or cannot be removed by surgery. Ongoing study 27 August 2015; estimated primary completion date: 31 December 2020. ">NCT02408861</a>; <a href="./references#CD012556-bbs2-0012" title="HerreraAF , BartlettNL , RamchandrenR , VoseJM , MoskowitzAJ , FeldmanTA , et al. Preliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood2016;128(22):1105. HerreraAF , MoskowitzAJ , BartlettNL , VoseJM , RamchandrenR , FeldmanTA , et al. Interim results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Hematological Oncology2017;35:85‐6. HerreraAF , MoskowitzAJ , BartlettNL , VoseJM , RamchandrenR , FeldmanTA , et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood2018;131(11):1183‐94. ">NCT02572167</a>; <a href="./references#CD012556-bbs2-0013" title="Phase II, multi‐center trial of nivolumab and brentuximab vedotin in individuals with untreated Hodgkin lymphoma over the age of 60 years or unable to receive standard adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. Ongoing study 13 May 2016; estimated primary completion date: 13 November 2019. ">NCT02758717</a>; <a href="./references#CD012556-bbs2-0014" title="A phase I study of ipilimumab and nivolumab in advanced HIV‐associated solid tumours with expansion cohorts in HIV‐associated solid tumours and a cohort of HIV‐associated classical Hodgkin's lymphoma. Ongoing study 27 August 2015; estimated primary completion date: 31 December 2020. ">NCT02927769</a>; <a href="./references#CD012556-bbs2-0015" title="Ibrutinib and nivolumab in treating adults with relapsed or refractory classical Hodgkin's lymphoma. Ongoing study 20 December 2016; estimated primary completion date: 31 May 2019 (final data collection date for primary outcome). ">NCT02940301</a>; <a href="./references#CD012556-bbs2-0016" title="Nivolumab with Epstein Barr virus specific T cells (EB‐VSTS), relapsed/refractory EBV positive lymphoma (PREVALE). Ongoing study 16 February 12016; estimated primary completion date: 16 April 2019 (final data collection date for primary outcome). ">NCT02973113</a>; <a href="./references#CD012556-bbs2-0017" title="Nivolumab and AVD in early‐stage unfavourable classical Hodgkin lymphoma (NIVAHL). Ongoing study 21 February 2017; estimated primary completion date: December 2018 (final data collection date for primary outcome). ">NCT03004833</a>; <a href="./references#CD012556-bbs2-0018" title="Nivolumab, ifosfamide, carboplatin, and etoposide as second‐line therapy in treating adults with refractory or relapsed Hodgkin lymphoma. Ongoing study 8 May 2017; estimated primary completion date: 24 April 2019 (final data collection date for primary outcome). ">NCT03016871</a>; <a href="./references#CD012556-bbs2-0019" title="(B)VD followed by nivolumab as frontline therapy for higher risk patients with classical Hodgkin lymphoma. Ongoing study 25 January 2017; estimated primary completion date: January 2020 (final data collection date for primary outcome). ">NCT03033914</a>; <a href="./references#CD012556-bbs2-0020" title="Nivolumab and brentuximab vedotin after stem cell transplant in treating patients with relapsed or refractory high‐risk classical Hodgkin lymphoma. Ongoing study 3 May 2017; estimated primary completion date: April 2019 (final data collection date for primary outcome). ">NCT03057795</a>; <a href="./references#CD012556-bbs2-0021" title="A study of nivolumab plus brentuximab vedotin versus brentuximab vedotin alone in patients with advanced stage classical Hodgkin lymphoma, who are relapsed/ refractory or who are not eligible for autologous stem cell transplant (CheckMate 812). Ongoing study 16 May 2017; estimated primary completion date: 29 November 2020 (final data collection date for primary outcome). ">NCT03138499</a>; <a href="./references#CD012556-bbs2-0022" title="Study to assess the safety of nivolumab in the treatment of metastatic melanoma, lung cancer, renal cancer, squamous cell carcinoma of the head and neck, and chronic Hodgkin's lymphoma in adults in Mexico. Ongoing study 17 July 2017; estimated primary completion date: 1 April 2019 (final data collection date for primary outcome). ">NCT03161613</a>). The publication of the results of these studies will necessitate an update of this review. The conclusions of this updated review could differ from those of the present review, and may allow a better judgement about the efficacy and safety of nivolumab. </p> <p>One of the primary outcomes of this review was OS, due to its clinical relevance and its importance for participants. Moreover, it is a commonly accepted measure of the benefit of cancer treatment, as well as an endpoint that is not subject to bias by the evaluator. Two studies reported that median survival was not reached after six months (100% of participants were alive) or 12 months of follow‐up. Two of the three cohorts of one study reported survival rates over 94%. However, data were not reported for the third cohort within this trial. </p> <p>The other primary outcome of this review, QoL, is of utmost importance for patients, especially those with several pretreatments. One of three cohorts from one study reported QoL but follow‐up data were lacking, therefore an overall assessment was not possible. Detailed data for all three study cohorts might help to assess QoL sufficiently. </p> </section> <section id="CD012556-sec-0091"> <h3 class="title" id="CD012556-sec-0091">Quality of the evidence</h3> <p>All three trials were prospectively planned, non‐randomised and uncontrolled trials leading to potential high risk of bias. Currently, there is no standard instrument available to assess risk of bias for this type of trials. We used the form developed by the Cochrane Childhood Cancer Group. </p> <p>As we included three small observational trials only (altogether fewer than 300 participants), the certainty of evidence was low to very low for most of the outcomes (see <a href="http://gdt.guidelinedevelopment.org/app/#projects/p_skoetzn_cc7ed15c-c238-4021-81f9-1c8d192dd3b6/evidence-syntheses/C2471758-A808-8FBF-986C-FEFFB65F5CCD/quality-of-evidence" target="_blank">interactive Summary of Findings table</a> and Summary of findings table 1). </p> </section> <section id="CD012556-sec-0092"> <h3 class="title" id="CD012556-sec-0092">Potential biases in the review process</h3> <p>We tried to avoid bias by dually carrying out all relevant processes (searching, data collection, analysis). We performed a sensitive search strategy and searched all relevant data of international HL conferences and study registries to detect potential publication bias. In addition, two authors of this review (AE, BvT) are very experienced in clinical studies on HL (AE is the head of the GHSG). Therefore, we are confident that we have identified all studies relevant to the review question. We are not aware of any obvious flaws in our review process. </p> </section> <section id="CD012556-sec-0093"> <h3 class="title" id="CD012556-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge this is the first comprehensive systematic review focusing on nivolumab for adults with HL. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012556-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/urn:x-wiley:14651858:media:CD012556:CD012556-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_t/tCD012556-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012556-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012556-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/urn:x-wiley:14651858:media:CD012556:CD012556-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_t/tCD012556-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012556-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/media/CDSR/CD012556/image_n/nCD012556-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012556-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Nivolumab compared to no other intervention for adults with Hodgkin's lymphomas</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Nivolumab for adults with Hodgkin's lymphoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with Hodgkin's lymphoma </p> <p><b>Settings: i</b>npatient or outpatient cancer care </p> <p><b>Intervention:</b> nivolumab </p> <p><b>Comparison:</b> none </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impacts</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS</b><br/> follow‐up: range 6‐27 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012556-bbs2-0002" title="ArmandP , EngertA , YounesA , FanaleM , SantoroA , ZinzaniP L , et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase II CheckMate 205 Trial. Journal of Clinical Oncology2018;36(14):1428‐39. ArmandP , ShippMA , KuruvillaJ , CollinsGP , RamchandrenR , TimmermanJ , et al. A phase 2 study of a nivolumab (nivo)‐containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): study 205 Cohort D. Journal of Clinical Oncology. 2016; Vol. 34:15. EngertA , FanaleM , SantoroA , ArmandP , AnsellS , ZinzaniP L , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the multicohort multicenter phase 2 CheckMate 205 trial. Haematologica. 2017; Vol. 102:145. EngertA , HirjiI , TaylorF , BennettB , CocksK , KatoK , et al. Quality‐of‐life outcomes in patients with classical Hodgkin lymphoma treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase 2 study. Haematologica. 2016; Vol. 101:73. EngertA , SantoroA , ShippM , ZinzaniPL , TimmermanJ , AnsellS , et al. CheckMate 205: a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin. Haematologica2016;101:319. EngertA , TaylorF , BennettB , ChenC , CocksK , McDonaldJ , et al. Effect of nivolumab on patient‐reported outcomes in patients with relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: results from the multicohort phase 2 CheckMate 205 study. Blood. 2017; Vol. 130, issue Suppl. EngertA , TaylorF , BennettB , HirjiI , CocksK , McDonaldJ , et al. Patient subgroup analysis of quality‐of‐life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1831. FanaleM , EngertA , YounesA , ArmandP , AnsellS , ZinzaniPL , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow‐up of the phase 2 CheckMate 205 trial. Hematological Oncology. 2017; Vol. 35:135‐6. JägerU , EngertA , FanaleM , SantoroA , ArmandP , AnsellS , et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow‐up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncology Research and Treatment. 2017; Vol. 40:13‐4. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleM , et al. Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐nave patients. British Journal of Haematology. 2017; Vol. 176:7‐8. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22. TimmermanJM , EngertA , YounesA , SantoroA , ArmandP , FanaleMA , et al. CheckMate 205 update with minimum 12‐month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016; Vol. 128, issue 22:1110. YounesA , SantoroA , ShippM , ZinzaniPL , TimmermanJM , AnsellS , et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem‐cell transplantation and brentuximab vedotin: a multicentre, multicohort, single‐arm phase 2 trial. Lancet Oncology2016;17(9):1283‐94. YounesA , SantoroA , ZinzaniPL , TimmermanJ , AnsellSM , ArmandP , et al. CheckMate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) ‐ a phase 2 study. Journal of Clinical Oncology. 2016; Vol. 34. ZinzaniPL , EngertA , YounesA , SantoroA , AnsellS , TimmermanJ , et al. CheckMate 205 Cohort C: nivolumab in patients with classical Hodgkin lymphoma after prior brentuximab vedotin and autologous hematopoietic stem cell transplantation. Haematologica. 2016; Vol. 101:43‐4. ">CheckMate 205</a> reported that median OS has not been reached after a median follow‐up of 18 months. <a href="./references#CD012556-bbs2-0003" title="HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , AndoK , et al. Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO‐4538‐15): an interim analysis. Journal of Clinical Oncology. 2016; Vol. 34. MaruyamaD , HatakeK , KinoshitaT , FukuharaN , ChoiI , TaniwakiM , et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Science2017;108(5):1007‐12. ">Hatake 2016</a> reported 100% OS after 6 months. </p> <p>A retrospective analysis of participants with third relapse of cHL not treated with nivolumab shows a 6‐month OS of 90% and a 12 month OS of 73%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>260<br/> (2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b><br/> follow‐up: mean 7 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Both the EQ‐5D visual analogue scale (and the EORTC QLQ‐C30 indicated improved QoL for those participants who filled out the forms. (EQ‐5D: from 62 (standard deviation (SD) 30) at baseline (72 (90%) participants) to 80 (SD 18) at week 33 (44 (55%) participants); EORTC QLQ‐C30 suggested improvement from baseline across functional, symptom and global health scores) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80<br/> (1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PFS</b><br/> follow‐up: range 6 months to 23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 trials reported 6‐month PFS of 60‐86%. In the other trial, median PFS was 12‐18 months. A retrospective analysis of third relapsed people with cHL not treated with nivolumab demonstrated a 6‐month PFS of 76% and a 12‐month PFS of 51%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response rate</b><br/> follow‐up: range 6‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Complete response rate was 12‐29% depending on inclusion criteria and participants' previous treatments </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment‐related mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade 3 or 4 AEs</b><br/> follow‐up: range 8‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 trial reported drug‐related AEs only (fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%)). The other 2 trials reported 23% to 52% AEs. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>283<br/> (3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SAEs</b><br/> follow‐up: range 16‐23 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2% of participants had infusion reactions and 1% pneumonitis (drug‐related SAEs).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>243<br/> (1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE:</b> adverse event; <b>cHL:</b> classical Hodgkin's lymphoma; <b>CI:</b> confidence interval; <b>EORTC:</b> European Organisation for Research and Treatment of Cancer; <b>OS:</b> overall survival; <b>PFS:</b> progression‐free survival; <b>QoL:</b> quality of life; <b>SAE:</b> serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Since all included studies where uncontrolled studies, the certainty of the evidence for all outcomes started at "low" (2 points) </p> <p><sup>b</sup>Different study populations with different previous therapeutic regimen and various follow‐up times led to inconsistency (downgraded 1 point). </p> <p><sup>c</sup>Only a subset of participants was evaluated (cohort B, 80 participants, but only 44 filled out follow‐up data) (downgraded by 1 point). </p> <p><sup>d</sup>Small number of events leads to imprecision (downgraded 1 point). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Nivolumab compared to no other intervention for adults with Hodgkin's lymphomas</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012556-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>External validity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias</b> (representative: yes/no) </p> <p> <ul id="CD012556-list-0013"> <li> <p>if the described study group consisted of &gt; 80% of the Hodgkin's lymphoma participants treated with nivolumab in the original cohort </p> </li> </ul> </p> <p><b>or</b> </p> <p> <ul id="CD012556-list-0014"> <li> <p>if it was a random sample with respect to the cancer treatment and important prognostic factors </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0015"> <li> <p>if the mean/median or range of the cumulative nivolumab dose was mentioned</p> </li> </ul> </p> <p><b>and</b> </p> <p> <ul id="CD012556-list-0016"> <li> <p>when it was described what prior treatment (including the received doses) was given</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition bias</b> (adequate: yes/no) </p> <p> <ul id="CD012556-list-0017"> <li> <p><br/>if the outcome was assessed for &gt; 90% of the study group of interest (++) </p> </li> </ul> </p> <p><br/><b>or</b> </p> <p> <ul id="CD012556-list-0018"> <li> <p>if the outcome was assessed for 60‐90% of the study group of interest (+)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no)<br/></p> <p> <ul id="CD012556-list-0019"> <li> <p>if the length of follow‐up was mentioned</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detection bias</b> (blind: yes/no) </p> <p> <ul id="CD012556-list-0020"> <li> <p><br/>if the outcome assessors were blinded to the investigated determinant </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0021"> <li> <p><br/>if the outcome definition was objective and precise, and the method of detection was provided </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk estimation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Confounding</b>(adjustment for other factors: yes/no) </p> <p> <ul id="CD012556-list-0022"> <li> <p>if important prognostic factors (i.e. age, gender, cotreatment) or follow‐up were taken adequately into account </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analyses</b> (well defined: yes/no) </p> <p> <ul id="CD012556-list-0023"> <li> <p>if a risk ratio, odds ratio, attributable risk, linear or logistic regression model, mean difference or Chi<sup>2</sup> was calculated </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012556.pub2/full#CD012556-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012556.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012556-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012556-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012556-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD012556-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012556-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012556-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012556-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012556\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012556\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012556\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012556\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012556\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012556.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012556.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012556.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012556.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012556.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719852068"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012556.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719852072"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012556.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df2da3e9d937f',t:'MTc0MDcxOTg1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 